These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
135 related articles for article (PubMed ID: 2934580)
21. [Buserelin therapy in postmenopausal patients with advanced breast carcinoma]. Vici P; Veltri E; Carpano S; Di Lauro L; Lopez M Clin Ter; 1991 Feb; 136(3):195-9. PubMed ID: 1827382 [TBL] [Abstract][Full Text] [Related]
22. Suppression of gonadotrophin secretion does not reverse premature ovarian failure. Ledger WL; Thomas EJ; Browning D; Lenton EA; Cooke ID Br J Obstet Gynaecol; 1989 Feb; 96(2):196-9. PubMed ID: 2522795 [TBL] [Abstract][Full Text] [Related]
23. Treatment with a luteinising-hormone-releasing-hormone analogue (buserelin) in premenopausal patients with metastatic breast cancer. Klijn JG; de Jong FH Lancet; 1982 May; 1(8283):1213-6. PubMed ID: 6122975 [TBL] [Abstract][Full Text] [Related]
24. [Effect of the steroid sex hormones on the LH and FSH responses to LHRH in the normal subject]. Lemarchand-Béraud T; Reymond M; Rappoport G; Magrini G; Gomez J Pathol Biol (Paris); 1975 Dec; 23(10):917-22. PubMed ID: 772543 [TBL] [Abstract][Full Text] [Related]
25. Treatment of patients with advanced cancer of the prostate using a slow-release (depot) formulation of the LHRH agonist ICI 118630 (Zoladex). Walker KJ; Turkes AO; Turkes A; Zwink R; Beacock C; Buck AC; Peeling WB; Griffiths K J Endocrinol; 1984 Nov; 103(2):R1-4. PubMed ID: 6238116 [TBL] [Abstract][Full Text] [Related]
26. Goserelin (Zoladex) in premenopausal advanced breast cancer: duration of response and survival. Dixon AR; Robertson JF; Jackson L; Nicholson RI; Walker KJ; Blamey RW Br J Cancer; 1990 Nov; 62(5):868-70. PubMed ID: 2147110 [TBL] [Abstract][Full Text] [Related]
27. Endocrine effects of adjuvant chemotherapy and long-term tamoxifen administration on node-positive patients with breast cancer. Jordan VC; Fritz NF; Tormey DC Cancer Res; 1987 Jan; 47(2):624-30. PubMed ID: 3098415 [TBL] [Abstract][Full Text] [Related]
28. Comparison of mammalian luteinizing hormone releasing hormone (LH-RH), and of an analog (ICI 118630), on luteinizing hormone and ovarian steroid (progesterone, oestradiol) secretions in laying hens. (Gallus domesticus). Guémené D; Williams JB Life Sci; 1986 Aug; 39(6):541-7. PubMed ID: 2942749 [TBL] [Abstract][Full Text] [Related]
29. Influence of serum follicle stimulating hormone to luteinizing hormone ratio during buserelin acetate-induced pituitary desensitization on ovarian response to exogenous gonadotrophins in an in-vitro fertilization and embryo transfer programme. Yamashita T; Ishimaru T; Fujishita A; Kawano M; Yamabe T Hum Reprod; 1996 Aug; 11(8):1615-9. PubMed ID: 8921103 [TBL] [Abstract][Full Text] [Related]
30. Contraception with an LHRH agonist: effect on gonadotrophin and steroid secretion patterns. Kuhl H; Jung C; Taubert HD Clin Endocrinol (Oxf); 1984 Aug; 21(2):179-88. PubMed ID: 6432376 [TBL] [Abstract][Full Text] [Related]
32. Estrogenic action of tamoxifen in women treated with luteinizing hormone-releasing hormone agonists (goserelin)--lack of shrinkage of uterine fibroids. Lumsden MA; West CP; Hillier H; Baird DT Fertil Steril; 1989 Dec; 52(6):924-9. PubMed ID: 2531684 [TBL] [Abstract][Full Text] [Related]
33. Pituitary function, ovarian follicular growth, and plasma concentrations of 17 beta-estradiol and progesterone in prepubertal heifers during and after treatment with the luteinizing hormone-releasing hormone agonist deslorelin. Bergfeld EG; D'Occhio MJ; Kinder JE Biol Reprod; 1996 Apr; 54(4):776-82. PubMed ID: 8924496 [TBL] [Abstract][Full Text] [Related]
34. The effect of danazol and the LHRH agonist analogue goserelin (Zoladex) on the biological activity of luteinizing hormone in women with endometriosis. Maouris P; Dowsett M; Rose G; Edmonds DK; Rothwell C; Robertson WR Clin Endocrinol (Oxf); 1990 Oct; 33(4):539-46. PubMed ID: 2146047 [TBL] [Abstract][Full Text] [Related]
35. Effects of gonadotropin-releasing hormone and its agonists on prolactin secretion from normal and tumorous pituitary cells. Lamberts SW; Uitterlinden P; Reubi JC; de Jong FH Neuroendocrinology; 1989 Feb; 49(2):157-63. PubMed ID: 2524674 [TBL] [Abstract][Full Text] [Related]
36. Goserelin depot in the treatment of premenopausal advanced breast cancer. Blamey RW; Jonat W; Kaufmann M; Bianco AR; Namer M Eur J Cancer; 1992; 28A(4-5):810-4. PubMed ID: 1388037 [TBL] [Abstract][Full Text] [Related]
37. Therapy in premenopausal women with advanced, oestrogen positive or/and progesterone positive breast cancer: surgical oophorectomy versus the LHRH analogue, Zoladex. Robert NJ; Dalton WS; Osborne CK; Abeloff M Horm Res; 1989; 32 Suppl 1():221-2. PubMed ID: 2533155 [TBL] [Abstract][Full Text] [Related]
38. Effects of bovine follicular fluid on gonadotrophin secretion in intact and chronically ovariectomized ewes before and after desensitization of pituitary gonadotrophs to gonadotrophin-releasing hormone. Knight PG; Castillo RJ J Endocrinol; 1988 Jun; 117(3):431-9. PubMed ID: 2969030 [TBL] [Abstract][Full Text] [Related]
39. The effects of chronic treatment with LHRH on gonadotrophin secretion and pituitary responsiveness to LHRH in women with secondary hypogonadism. Vaughan Williams CA; McNeilly AS; Baird DT Clin Endocrinol (Oxf); 1983 Jul; 19(1):9-19. PubMed ID: 6413100 [TBL] [Abstract][Full Text] [Related]
40. Endocrine and clinical effects of an LHRH analogue in pretreated advanced breast cancer. Lissoni P; Barni S; Crispino S; Cattaneo G; Tancini G Tumori; 1988 Jun; 74(3):303-8. PubMed ID: 2840764 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]